Women's Health Innovator Granata Bio Raises $14M Series A led by GV to Accelerate Fertility Biopharma Pipeline
Summary
BOSTON, Jan. 16, 2024 /PRNewswire/ -- Granata Bio, Inc. a biopharma company focused on invigorating the $3.6B global infertility medication market, today announced the close of a $14M Series A funding round led by GV (Google Ventures). The company gained immediate traction by designing innovative clinical development programs aimed at optimizing outcomes for study subjects while assessing the safety and efficacy of investigational products. "Granata is taking a novel approach to both address current market dynamics and to develop unique products targeting unmet needs in womens health," says CEO Evan Sussman. Notable investment outcomes include Uber, Nest, Slack, GitLab, Duo Security, Flatiron Health, Verve Therapeutics, and One Medical. We currently offer over 600 clinically relevant medical devices to womens healthcare providers, including testing and treatment options.CooperSurgical is a wholly-owned subsidiary of CooperCompanies.